MDM2, MDM2 proto-oncogene, 4193

N. diseases: 702; N. variants: 30
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group BEFREE A total of 787 invasive breast tumors included in a clinically annotated multiethnic population-based tissue microarray (TMA) were screened utilizing commercially available antibodies to p53 and MDM2, and a newly developed monoclonal antibody recognizing MDM2-C. 30470976 2019
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group CTD_human The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer. 26229107 2015
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group BEFREE We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival. 20021639 2009
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. 19144119 2009
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Our data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors. 18547962 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. 18281248 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. 17719241 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. 18828900 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group BEFREE MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. 18828900 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Our data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors. 18547962 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53. 18317451 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. 17909070 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. 17387621 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group BEFREE Among homozygous carriers of the common MDM2 SNP309 allele (T/T), a mutant p53 status (risk ratio [RR] of death = 2.33, 95% CI = 1.08 to 5.03) and aberrant p53 protein expression (RR = 2.61, 95% CI = 1.22 to 5.57) in breast tumors were associated with poor survival. 16818855 2006
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. 16434608 2006
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 GeneticVariation group LHGDN Among homozygous carriers of the common MDM2 SNP309 allele (T/T), a mutant p53 status (risk ratio [RR] of death = 2.33, 95% CI = 1.08 to 5.03) and aberrant p53 protein expression (RR = 2.61, 95% CI = 1.22 to 5.57) in breast tumors were associated with poor survival. 16818855 2006
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF. 14729628 2004
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Our findings support the hypothesis that the elevated levels of hdm2 expression reported in cancers such as ERalpha(+ve) breast tumors play an important role in the development of these tumors. 12750288 2003
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Our findings support the hypothesis that the elevated levels of hdm2 expression reported in cancers such as ERalpha(+ve) breast tumors play an important role in the development of these tumors. 12750288 2003
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE Here, the expression of mdm2 mRNA subsequent to phorbol 12,13-dibutyrate (PDB) or diethylstilbestrol (DES) treatment was analyzed in human breast tumor-derived GI-101A cell line. 12231395 2002
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group LHGDN Distinct promoter usage of mdm2 gene in human breast cancer. 11956627 2002
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group LHGDN Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. 11859876 2002
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 Biomarker group BEFREE TP53 mutations were identified in 7/36 (19%) breast tumors and HDM2 amplification in 2/30 (7%) tumors. 11336244 2001
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE The p60 form of MDM2 is a significant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. 9840926 1998
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.400 AlteredExpression group BEFREE MDM2 RNA expression levels were analysed in a subset of 57 breast tumours and overexpression was observed in 4/57 (7%) of the tumours. 8980401 1996